ArticleThe Journal of biological chemistry2026
Ubiquitin E3 ligase MYCBP2 targets KIF14 and contributes to acute myeloid leukemia progression.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a challenging hematological malignancy characterized by poor clinical outcomes. This study investigates the role of MYCBP2 in AML progression, focusing on its interaction with KIF14 and its involvement in ubiquitin-mediated processes. We found that MYCBP2 is overexpressed in AML samples compared to normal tissues, with high expression correlating with adverse clinical outcomes. Knockdown of MYCBP2 using siRNA significantly inhibited cell proliferation and promoted apoptosis in MOLM-13 and HL-60 AML cell lines. Flow cytometry revealed that MYCBP2 knockdown leads to cell cycle arrest in the G0/G1 phase. Gene Set Enrichment Analysis indicated that MYCBP2 is associated with the Ubiquitin-Mediated Proteolysis pathway, regulating KIF14 protein stability through ubiquitination. High KIF14 expression was linked to better overall survival, and KIF14 knockdown partially reversed the effects of MYCBP2 knockdown on cell viability and apoptosis. In vivo studies demonstrated that MYCBP2 knockdown significantly reduced tumor growth and enhanced apoptosis in a xenograft model. These findings support that MYCBP2 promotes AML progression at least in part by negatively regulating KIF14 stability, highlighting MYCBP2 as a potential therapeutic target. Future research should explore targeted therapies aimed at MYCBP2 and its downstream pathways to improve treatment strategies for AML.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.